MX2017004476A - Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. - Google Patents

Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.

Info

Publication number
MX2017004476A
MX2017004476A MX2017004476A MX2017004476A MX2017004476A MX 2017004476 A MX2017004476 A MX 2017004476A MX 2017004476 A MX2017004476 A MX 2017004476A MX 2017004476 A MX2017004476 A MX 2017004476A MX 2017004476 A MX2017004476 A MX 2017004476A
Authority
MX
Mexico
Prior art keywords
powder
composition
weight
stability
dry powder
Prior art date
Application number
MX2017004476A
Other languages
English (en)
Inventor
Zanellotti Laura
Veneziani Cristina
BUTTI Heike
Caponetti Giovanni
Maggi Loretta
Original Assignee
Eratech S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eratech S R L filed Critical Eratech S R L
Publication of MX2017004476A publication Critical patent/MX2017004476A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente invencion se refiere a formulaciones de inhalacion de farmacos en forma de polvo seco para administracion por inhalacion, que se pueden suministrar como tales con un inhalador y proporcionan alta capacidad de liberacion, respirabilidad y estabilidad. En particular, la invencion se refiere a una composicion farmaceutica para uso por inhalacion en forma de polvo que comprende un primer polvo que comprende al menos un polvo (a1) que comprende un agente activo o una sal farmacéuticamente aceptable del mismo, n una cantidad mayor a 1% en peso del polvo, leucina en una cantidad del 5 al 70% en peso de dicho polvo, un azucar en una cantidad del 20 al 90% en peso del polvo; y un segundo polvo que comprende una mezcla de una primera lactosa que tiene un X50 de 35 a 75 um, con una segunda lactosa que tiene un X50 de 1.5 a 10 um, el contenido de las primera y segunda lactosas en la mezcla es del 85% al 96% y del 4% al 15% respectivamente. La relación en peso entre el primer polvo y el segundo polvo es de 1/5 a 1/100, y la composicion tiene una fraccion de partículas finas (FPF) superior al 60% y una fraccion entregada (DF) superior al 85%.
MX2017004476A 2014-10-08 2015-10-07 Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. MX2017004476A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141761 2014-10-08
PCT/EP2015/073188 WO2016055544A1 (en) 2014-10-08 2015-10-07 Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation

Publications (1)

Publication Number Publication Date
MX2017004476A true MX2017004476A (es) 2017-11-20

Family

ID=51904067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004476A MX2017004476A (es) 2014-10-08 2015-10-07 Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.

Country Status (14)

Country Link
US (1) US10517828B2 (es)
EP (1) EP3203983A1 (es)
JP (1) JP6919093B2 (es)
KR (1) KR102462058B1 (es)
CN (1) CN107205936B (es)
AU (2) AU2015330010A1 (es)
CA (1) CA2962531C (es)
CO (1) CO2017004504A2 (es)
EA (1) EA035740B1 (es)
IL (1) IL251472B (es)
MX (1) MX2017004476A (es)
MY (1) MY191712A (es)
WO (1) WO2016055544A1 (es)
ZA (1) ZA201703125B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3178769A1 (en) 2020-05-18 2021-11-25 Jonas Savmarker New pharmaceutical composition for drug delivery
CN112125818A (zh) * 2020-09-23 2020-12-25 山东瑞博龙化工科技股份有限公司 一种制备n,n-二乙基丙烯酰胺的系统及工艺
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
CN115400103B (zh) * 2022-09-22 2023-11-24 苏州易合医药有限公司 一种多孔性呼吸颗粒及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
ES2632461T3 (es) * 2000-06-27 2017-09-13 Vectura Limited Formulaciones para su uso en dispositivos inhaladores
JP2005507881A (ja) * 2001-09-17 2005-03-24 グラクソ　グループ　リミテッド 乾燥粉末医薬製剤
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
CA2677347A1 (en) * 2007-02-09 2008-08-14 Jill K. Sherwood Stable pharmaceutical drug aerosols
CN102811715A (zh) * 2009-12-08 2012-12-05 悉尼大学 可吸入制剂
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
CN103501642B (zh) * 2011-03-02 2018-07-24 日本烟草产业株式会社 含香料片材及其制造方法、及包含该片材的吸烟物品
WO2013109220A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising tiotropium, formoterol and budesonide
PT3527199T (pt) 2012-01-25 2022-11-08 Chiesi Farm Spa Formulação de um pó seco compreendendo um corticosteroide e um beta adrenérgico para administração por inalação
EA036153B1 (ru) * 2012-07-05 2020-10-06 Арвен Айлак Санайи Ве Тиджарет А.С. Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор

Also Published As

Publication number Publication date
KR102462058B1 (ko) 2022-11-01
JP6919093B2 (ja) 2021-08-18
CA2962531C (en) 2023-05-23
AU2015330010A1 (en) 2017-04-27
EP3203983A1 (en) 2017-08-16
EA035740B1 (ru) 2020-08-03
CN107205936B (zh) 2021-07-16
AU2021200503A1 (en) 2021-02-25
IL251472A0 (en) 2017-05-29
EA201700182A1 (ru) 2017-09-29
MY191712A (en) 2022-07-09
US10517828B2 (en) 2019-12-31
WO2016055544A1 (en) 2016-04-14
KR20170093114A (ko) 2017-08-14
JP2017530993A (ja) 2017-10-19
AU2021200503B2 (en) 2023-01-12
BR112017007182A2 (pt) 2017-12-19
CO2017004504A2 (es) 2017-10-20
IL251472B (en) 2021-08-31
ZA201703125B (en) 2020-05-27
CN107205936A (zh) 2017-09-26
US20170333349A1 (en) 2017-11-23
CA2962531A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
NZ723838A (en) Cannabinoid compositions and uses
WO2015120110A3 (en) Novel pharmaceutical formulations
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
NZ627837A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
MX2015014513A (es) Composicion que comprende sulfato de salbutamol.
EA201800266A1 (ru) Антивирусная фармацевтическая композиция
BR112015020443A8 (pt) formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
WO2014167579A3 (en) Stable pharmaceutical compositions of tadalafil
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
WO2015100348A8 (en) Keloid reduction using topical allantoin
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
MX2017004583A (es) Composicion farmaceutica que contiene budesonida y formoterol.
BR112017021111A2 (pt) processo para fabricação de misturas de pós secos
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: ZAMBON S.P.A.